Human adenosine deaminase (EC 3.5.4.4), a key purine salvage enzyme essential for immune competence, has been overproduced in Spodoptera frugiperda cells and in Trichoplusia ni (cabbage looper) larvae infected with recombinant baculovirus. The coding sequence of human adenosine deanunase was recombined into a baculovirus immediately downstream from the strong polyhedrin gene promoter. Approximately 60 hr after infection of insect cells with the recombinant virus, maximal levels of intracellular adenosine deaminase mRNA, protein, and enzymatic activity were detected. The recombinant human adenosine deaminase represented 10% of the total cellular protein and exhibited a specific activity of 70 units/mg of protein in crude homogenate. This specific activity is 70-350 times greater than that exhibited by the enzyme in homogenates of the two most abundant natural sources of human adenosine deaminase, thymus and leukemic cells. When the recombinant virus was iinjected into insect larvae, the maximum recombinant enzyme was produced 4 days postinfection and represented about 2% of the total insect protein with a specific activity of 10-25 units/mg of protein.
cells. When the recombinant virus was iinjected into insect larvae, the maximum recombinant enzyme was produced 4 days postinfection and represented about 2% of the total insect protein with a specific activity of 10-25 units/mg of protein.
The recombinant human adenosine deaninase was purified to homogeneity from both insect cells and larvae and demonstrated to be identical to native adenosine deaminase purified from human cells with respect to molecular weight, interaction with polyclonal anti-adenosine deaminase antibody, and enzymatic properties. A pilot purification yielded 8-9 mg of homogeneous enzyme from 22 larvae. The production of large quantities of recombinant human adenosine deaminase in insect larvae is inexpensive and rapid and eliminates the need for specialized facilities for tissue culture. This method should be applicable to large-scale production of many recombinant proteins.
Adenosine deaminase (ADA; adenosine-aminohydrolase, EC 3.5.4.4) catalyzes the conversion ofadenosine and deoxyadenosine to inosine and deoxyinosine. In humans deficiency of this purine salvage enzyme is associated with severe immunodeficiency and lymphopenia in both B-and T-cell lineages (1, 2) . Pharmacologic agents that inhibit ADA induce lymphopenia and have been employed in the treatment of certain leukemias. The enzyme has been isolated as a single polypeptide from erythrocytes (Mr 36,000; ref. 3) and from leukemic cells and thymus (Mr 41,000; ref. 4) . In lung and kidney, ADA is associated with a large "complexing protein"
(Mr 298,000; ref. 5 ) of unknown function. While much is now known about the enzymatic activity of human ADA, including its interaction with various substrates (4) and inhibitors (6) (7) (8) , no direct information is available concerning the enzyme active site. Although a preliminary analysis of crystals of murine ADA has been reported (9), the three-dimensional fine structure of the human enzyme is not known.
It has been suggested that the enzyme undergoes a conformational change upon inhibitor binding (6, 7) and that a reactive histidine group participates in catalysis of calf intestinal ADA (10) . However, lack of sufficient quantities of human ADA has precluded detailed structural studies of important enzyme domains.
Human thymus contains relatively abundant quantities of ADA (7), but the scarcity of this tissue has rendered impractical the purification of the large quantities of protein required for structural and mechanistic studies. We closed cups. Larvae (fourth instar) were sedated by incubation on ice for 15 min and then injected near the proleg (forward along the body cavity) with 10 ,ul of medium containing recombinant baculovirus. When optimum quantities of recombinant enzyme accumulated in the insects (4 days after injection), larvae were harvested and immediately frozen at -70°C.
ADA Assays. Cells were washed with phosphate-buffered saline, resuspended in 0.25 M potassium phosphate buffer, pH 7.4/1 mM 2-mercaptoethanol, and sonicated on ice (three 15-sec bursts). The sonicate was centrifuged (4°C) for 10 min in an Eppendorf centrifuge to clarify the supernatant solution. Larvae were added to extraction buffer (10 mM sodium acetate, pH 6.4/2 mM EGTA/8 mM benzamidine/10 mM 6-aminocaproic acid/1 mM phenylmethylsulfonyl fluoride) and homogenized on ice with a Polytron tissue disrupter (Brinkmann). The homogenate was centrifuged at 100,000 x g for 1 hr. The radioassay for ADA activity, which employs [8-14C] adenosine as the substrate, was described previously (13) . Protein was quantitated by the method of Lowry et al. (14) with bovine serum albumin as the standard.
Purification of Recombinant ADA. Frozen larvae (total, 7-8 g) were added to 20 ml of extraction buffer (see above) and homogenized (on ice) with two 15-sec bursts ofa Polytron set at medium speed. The crude extract (25 ml) was centrifuged at 20,000 x g for 1.5 hr. To remove viral DNA that would inhibit binding of ADA to the DEAE ion-exchange matrix, the clarified extract was treated with 28 mg of protamine sulfate that had been neutralized with KOH. The clarified supernatant from this step was applied to a 100-ml DEAESephadex column equilibrated in 10 mM sodium acetate (pH 6.4). The column was washed with 3 volumes of buffer and the ADA protein was eluted in the sodium acetate buffer containing 0.5 M NaCl. The eluate was brought to 70% saturation with ammonium sulfate and left at 40C overnight.
The ammonium sulfate precipitate was resuspended in 2.8 ml of phosphate-buffered saline (10 mM sodium phosphate/140 mM NaCl, pH 7.4) containing 1 mM EGTA and 0.02% sodium azide. The protein suspension was applied to a 50-ml adenosine-Sepharose (15) Fig. 1 ). After coinfection of Sf9 cells with the transfer-vector construct and wild-type baculovirus, three independent recombinant isolates were identified by plaque morphology screening (Fig. 2) . To confirm that these isolates contained ADA nucleic acid sequences, each culture was analyzed for the presence of ADA sequences by dot blot hybridization to a labeled ADA cDNA probe. Whereas uninfected wild-type Sf9 cell extracts did not exhibit hybridizable sequences, each of three isolates (8A, B, and C) did exhibit ADA sequences (data not shown).
Analysis of ADA enzymatic activity present in recombinant virus-infected cells is shown in Fig. 3 (11 ,ug) , proteins present in AcMNPV Li/huADA-infected cells; lanes 4 (11 ,ug) and 6 (11 ,ug) , proteins in wild-type Sf9 cells. Proteins in the other gel (Right) were subjected to electrophoretic transfer onto nitrocellulose and tested for reactivity with monospecific rabbit anti-human ADA. The antigen was detected by reaction with a peroxidase-coupled secondary antibody (Biogenex Labs, Dublin, CA). Lanes 9 and 18, 0.9 ,&g of purified human ADA standard; lanes 10 (5.5 ,ug), 12 (1.2 j&g), 14 (0.6 ,ug), and 16 (0.1 ,ug), uninfected cells; lanes 11 (5.5 Ag), 13 (1.1 ,ug), 15 To ensure that the kinetic properties of the enzyme were maintained throughout the vector manipulations, we determined the Km for the natural substrate, adenosine, as well as the Ki for a potent inhibitor, erythro-9-[3-(2-hydroxynonyl)]-adenine (EHNA). The Km for adenosine was 50 A&M and the Ki for EHNA in the reactions was calculated to be 15 nM. These values were identical to those reported for naturally occurring human ADA (16) .
Immunoreactive Human ADA in Virus-Infected Cells. SDS/ PAGE analysis of lysates of Sf9 cells infected with recombinant virus revealed a Coomassie blue-stained protein identical in molecular weight to ADA isolated from human thymus (Fig. 4, lanes 3 and 5) Fig. 4 ). However, the wholeinsect homogenates did appear to contain proteases as reflected in the SDS/PAGE profile (data not shown). Several strategies aimed at eliminating proteolysis were compared. Hemolymph, collected from each larva by bleeding, was assayed for ADA activity. However, the specific activity of ADA in this fluid was low in comparison to the whole homogenate and the extra effort required to collect the fluid was not warranted. Therefore, protease inhibitors (phenylmethylsulfonyl fluoride, benzamidine, 6-aminocaproic acid, and EGTA) were added to the solution used to homogenize frozen larvae. Under these conditions, intact ADA was readily detected in crude extracts (data not shown) and human ADA activity was not affected by the presence of these protease inhibitors. The specific activity of ADA ranged from 1.2 units/mg of protein on day 1 to 27 units/mg on day 4 (postinjection). Although >80o of the larvae were dead on day 5, they yielded ADA with a specific activity of 29 units/mg of protein. However, larvae were harvested routinely on day 4 following infection with the recombinant virus.
Purification of Recombinant Human ADA. The specific activity of human ADA in the larval homogenates was 10-300 times higher than the value obtained from human tissues that have been used traditionally to purify this enzyme. Therefore, we were able to simplify the purification protocol. A sample scheme is shown in Table 1 . For this preparation, 22 frozen larvae were used. ADA obtained by this procedure exhibited a specific activity of =400 units/mg of protein [a value we have consistently observed for homogeneous preparations of the enzyme obtained by our standard method (8) ] and was >95% pure on the basis of SDS/PAGE (Fig. 5, lanes  1-4) (17) . However, production of large quantities of recombinant protein by this approach requires access to specialized largescale tissue culture facilities as well as defined and expensive tissue culture media (17) . To circumvent these requirements, we investigated the infectivity of the recombinant baculoviBiochemistry: Medin et al.
Proc. Natl. Acad. Sci. USA 87 (1990) rus as well as the stability of the viral gene product in insect larvae. The activity of the polyhedrin promoter has been reported to be very high in larvae (18) , but others have reported a high mortality rate in inoculated larvae and suggested that coinfection with recombinant and wild-type baculoviruses is necessary to produce encapsidated recombinant virus particles that can be used for infection per os (19) . As demonstrated in this paper, injection of the recombinant baculovirus AcMNPV Li/huADA near the proleg caused negligible loss of larvae due to inoculation injury and resulted in expression of recombinant human ADA to 2-5% of the total insect protein. Maintenance and total manipulation of 40 larvae requires about 3 hr of labor per week. It was unnecessary to collect hemolymph from the insect, and the frozen larvae were homogenized whole. Purification of human ADA (9 mg) from this source (22 larvae) was accompliihed in three stages within 2 days. The number of larvae used in each purification can be easily manipulated so that with ADA it should be feasible to produce about 50 mg homogeneous protein in 2 days. By contrast, employing standard tissue culture techniques would require sophisticated instrumentation for bulk processing of large quantities of insect cells (20) and would incur a substantial investment in media, labor, and training.
The use ofthe larvae as host for viral replication represents an easy and inexpensive method for production of recombinant proteins. We have tested this method for production of another recombinant human protein, terminal deoxynucleotidyitransferase, and found equally efficient expression and stability ofthat enzyme in the insect larvae (3900 units/mg of protein as compared with [10] [11] [12] [13] [14] [15] units/mg of protein in calf thymus). It is our expectation that this procedure will be generally applicable for the production of a wide array of recombinant proteins.
